- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02962648
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®) (FERWON-EXT)
An Open-label, Multicentre, Extension Trial to Assess the Safety of Re-dosing of Intravenous Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Among the various formulations of parenteral iron that are currently available, iron isomaltoside/ferric derisomaltose may allow flexibility in terms of high and rapid dosing. Up to now, most clinical trials with intravenous (IV) iron treatment were of 4-12 weeks in duration; longer trials are warranted to follow-up on long-term safety.
The aim of the trial was to evaluate the safety and efficacy of IV iron isomaltoside/ferric derisomaltose re-dosing in subjects who were previously treated with iron isomaltoside/ferric derisomaltose in lead-in trials.
This was a 6-months extension trial lasting 26 weeks. Eligible subjects attended 5 visits: screening, baseline (subjects treated with a single IV dose of 1000 mg iron isomaltoside/ferric derisomaltose), and follow-up visits at week 2, 13, and 26 weeks after the IV dose, for safety and efficacy assessments.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Chula Vista, California, United States, 91910
- Pharmacosmos Investigational Site
-
La Mesa, California, United States, 91942
- Pharmacosmos Investigational Site 1
-
La Mesa, California, United States, 91942
- Pharmacosmos Investigational Site 2
-
Northridge, California, United States, 91324
- Pharmacosmos Investigational Site
-
Porterville, California, United States, 93257
- Pharmacosmos Investigational Site
-
-
Florida
-
Doral, Florida, United States, 33172
- Pharmacosmos Investigational Site
-
Hialeah, Florida, United States, 33012
- Pharmacosmos Investigational Site
-
Miami, Florida, United States, 33135
- Pharmacosmos Investigational Site
-
Miami, Florida, United States, 33147
- Pharmacosmos Investigational Site
-
Miami, Florida, United States, 33165
- Pharmacosmos Investigational Site
-
Miami Lakes, Florida, United States, 33014
- Pharmacosmos Investigational Site
-
West Palm Beach, Florida, United States, 33409
- Pharmacosmos Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pharmacosmos Investigational Site
-
Metairie, Louisiana, United States, 70006
- Pharmacosmos Investigational Site
-
New Orleans, Louisiana, United States, 70125
- Pharmacosmos Investigational Site
-
Shreveport, Louisiana, United States, 71101
- Pharmacosmos Investigational Site
-
-
New Jersey
-
Plainsboro, New Jersey, United States, 08536
- Pharmacosmos Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Pharmacosmos Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Pharmacosmos Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Pharmacosmos Investigational Site
-
San Antonio, Texas, United States, 78215
- Pharmacosmos Investigational Site 1
-
San Antonio, Texas, United States, 78215
- Pharmacosmos Investigational Site 2
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Completed one of the lead-in trials
- Randomised and dosed with iron isomaltoside/ferric derisomaltose in one of the lead-in trials.
- Haemoglobin (Hb) of ≤ 11 g/dL
- Screening serum ferritin (s-ferritin) ≤ 100 ng/mL, or ≤ 300 ng/mL if transferrin saturation (TSAT) ≤ 30 %
- Willingness to participate and signing the informed consent form (ICF)
Exclusion Criteria:
- Intravenous (IV) iron treatment between the lead-in trial and screening
- During 30-day period prior to screening or during the trial period; has or will be treated with a red blood cell transfusion, radiotherapy, and/or chemotherapy
- Received an investigational drug within 30 days of screening
- Decompensated liver cirrhosis or active hepatitis
- Pregnant or nursing women.
- Any other laboratory abnormality, medical condition, or psychiatric disorders which, in the opinion of the Investigator, will put the subject's disease management at risk or may result in the subject being unable to comply with the trial requirements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Iron isomaltoside/ferric derisomaltose
Administered IV
|
Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial. The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride from the site's supply and administered over approximately 20 minutes using IV infusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Adverse Drug Reactions (ADR)
Time Frame: Baseline to week 26
|
Safety Evaluate the number of subjects with adverse drug reactions (ADRs), defined as AEs that were assessed by the investigator as related or possible related to the investigational product. |
Baseline to week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions
Time Frame: Baseline to week 26
|
Safety. For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity terms that were included in the analysis were those that started or after the first dose of treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: Loss of consciousness; Seizure; Syncope; Unresponsiveness. The potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). Results show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions. |
Baseline to week 26
|
Composite Cardiovascular Adverse Events (AEs)
Time Frame: Baseline to week 26
|
Safety Results show the composite cardiovascular AEs, that started on or after the first dose of treatment (i.e. treatment emergent) up to month 6. The reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC). The potential cardiovascular AEs included the following:
Results show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs. |
Baseline to week 26
|
Time to First Composite Cardiovascular Safety AE
Time Frame: Baseline, week 2, 13, and 26
|
Safety Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the Clinical Endpoint Adjudication Committee (CEAC), were considered for this endpoint. Time to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. |
Baseline, week 2, 13, and 26
|
S-phosphate <2 mg/dL at Any Time From Baseline to Week 26
Time Frame: Baseline to week 26
|
Safety Results show the number of trial participants and their status of s-phosphate <2 mg/dL, at any time from baseline to week 26. |
Baseline to week 26
|
Change in Hb From Baseline to Week 2, 13, and 26
Time Frame: Baseline, week 2, 13, and 26
|
Efficacy. Change in Hb from baseline to week 2, 13, and 26. |
Baseline, week 2, 13, and 26
|
Change in S-ferritin From Baseline to Week 2, 13, and 26
Time Frame: Baseline, week 2, 13, and 26
|
Efficacy. Change in s-ferritin from baseline to week 2, 13, and 26. |
Baseline, week 2, 13, and 26
|
Change in Transferrin Saturation (TSAT) From Baseline to Week 2, 13, and 26
Time Frame: Baseline, week 2, 13, and 26
|
Efficacy Change in transferrin saturation (TSAT) from baseline to week 2, 13, and 26. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron. |
Baseline, week 2, 13, and 26
|
Change in S-iron From Baseline to Week 2, 13, and 26
Time Frame: Baseline, week 2, 13, and 26
|
Efficacy. Change in s-iron from baseline to week 2, 13, and 26. |
Baseline, week 2, 13, and 26
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-Monofer-IDA/CKD-EXT-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron Deficiency Anemia
-
Pennington Biomedical Research CenterRecruitingIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia TreatmentUnited States
-
Children's Hospital Los AngelesNot yet recruitingAnemia | Iron Deficiency Anemia | Anemia, Iron Deficiency | IDA - Iron Deficiency AnemiaUnited States
-
King's CollegeCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
Arrowhead Regional Medical CenterRecruitingIron Deficiency Anemia of PregnancyUnited States
-
Luzerner KantonsspitalRecruitingIron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron DeficienciesSwitzerland
-
Swiss Federal Institute of TechnologyUnited States Agency for International Development (USAID); Quadram Institute... and other collaboratorsCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)Peru
-
Children's Hospital Los AngelesWithdrawnAnemia | Iron-deficiency Anemia | Healthy ControlsUnited States
-
Baylor College of MedicineNational Heart, Lung, and Blood Institute (NHLBI)CompletedIron-deficiency | Iron Deficiency AnemiaUnited States
-
Iowa State UniversityCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron Deficiency Anaemia Due to Dietary CausesUnited States
-
Société des Produits Nestlé (SPN)CompletedIron-deficiency | Anemia | Iron Deficiency AnemiaPhilippines
Clinical Trials on Iron isomaltoside/ferric derisomaltose
-
Thomas Jefferson UniversityJawaharlal Nehru Medical CollegeActive, not recruitingIron Deficiency Anemia | Child Development | Iron Deficiency Anemia of Pregnancy | Iron Deficiency Anemia Treatment | Neurodevelopmental Disorder of Foetus | Fetal Neurodevelopmental DisorderIndia
-
Thomas Jefferson UniversityJawaharlal Nehru Medical College; Children's Investment Fund Foundation; S. Nijalingappa... and other collaboratorsActive, not recruitingIron Deficiency Anemia | Infant, Low Birth Weight | Anemia of PregnancyIndia
-
Thomas Jefferson UniversityJawaharlal Nehru Medical College; S. Nijalingappa Medical College; Raichur Institute...Active, not recruitingAutism Spectrum Disorder | Iron Deficiency Anemia | Neurodevelopmental AbnormalityIndia
-
Alberta Health Services, CalgaryPharmacosmos A/SNot yet recruitingGynecologic Cancer | Surgery | Anemia, Iron Deficiency
-
Pharmacosmos A/SCompletedIron Deficiency Anemia | Iron Deficiency AnaemiaUnited States
-
Pharmacosmos A/SCompletedIron Deficiency Anemia | Iron Deficiency AnaemiaUnited States
-
Saskatchewan Health Authority - Regina AreaSaskatchewan Centre for Patient-Oriented ResearchRecruitingIron Deficiency Anaemia in ChildbirthCanada
-
Michael KremkeAarhus University Hospital; Pharmacosmos A/S; University of AarhusCompleted
-
Pharmacosmos A/SCompletedIron Deficiency Anemia | Iron Deficiency AnaemiaUnited States
-
Pharmacosmos A/SCompletedChronic Kidney Disease | Iron Deficiency Anemia | Iron Deficiency AnaemiaUnited States